Skip to content
naulon

Not checkedNot checked for notices yet.

A case of lung adenocarcinoma harboring <it>EGFR</it> mutation and <it>EML4-ALK</it> fusion gene

Tanaka Hisashi, Hayashi Akihito, Morimoto Takeshi and 6 more

BMC Cancer · 2012

doi:10.1186/1471-2407-12-558 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Background</p> <p>Lung cancer is the leading cause of cancer-related death worldwide. Epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI) is used for the patients with <it>EGFR</it>-mutant lung cancer. Recently, phase III studies in the patients with <it>EGFR</it>-mutant demonstrated that EGFR-TKI monotherapy improved progression-free survival compared with platinum-doublet chemotherapy. The echinoderm microtubule-associated protein-like 4 (<it>EML4</it>) <it>-</it> anaplastic lymphoma kinase (<it>ALK</it>) fusion oncogene represents one of the newest molecular targets in non-small cell lung cancer (NSCLC). Patients who harbor <it>EML4-ALK</it> fusions have been associated with a lack of <it>EGFR</it> or <it>KRAS</it> mutations.</p> <p>Case presentation</p> <p>We report a 39-year-old patient diagnosed as adenocarcinoma harboring <it>EGFR</it> mutation and <it>EML4-ALK</it> fusion gene. We treated this patient with erlotinib as the third line therapy, but no clinical benefit was obtained.</p> <p>Conclusion</p> <p>We experienced a rare case with EGFR mutation and <it>EML4-ALK</it>. Any clinical benefit using EGFR-TKI was not obtained in our case. The therapeutic choice for the patients with more than one driver mutations is unclear. We needs further understanding of the lung cancer molecular biology and the biomarker infomation.</p>

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.